Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2017-05-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份质押及解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares held by the company's actual controllers. It details the number of shares pledged, dates, pledgees, and percentages of shareholding involved. There is no financial statement, earnings data, or management discussion. The document is short (1235 characters) and focuses on share pledge information, which is a capital structure related update. It is not an annual report, earnings release, or management report. It is not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges and releases by major shareholders.
2017-05-22 Chinese
关于召开2017年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening a 2017 first extraordinary general meeting (临时股东大会) of shareholders for 瑞康医药股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items related to bond issuance and financing proposals, registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not the results of the meeting or the minutes. It is not a report of voting results, nor a financial report or earnings release. It is a formal announcement to shareholders about the meeting itself, which fits the category of Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting. The document length (5957 characters) and detailed procedural content support this classification rather than a brief announcement or a report publication announcement.
2017-05-15 Chinese
第三届董事会第五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.). It includes multiple agenda items such as approval of proposals related to the issuance of corporate bonds, authorization for bond issuance, registration of short-term financing bonds, and scheduling of a shareholders meeting. The document contains voting results and detailed descriptions of the bond issuance plans, but it is not a financial report or earnings release. It is a formal announcement of board meeting decisions, which fits the category of Board/Management Information (MANG). The document length is 4678 characters, which is sufficient for a full announcement rather than a brief notice. There is no indication that this is a report publication announcement or a regulatory filing of a different nature. Therefore, the best classification is MANG.
2017-05-15 Chinese
2016年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2016 annual equity distribution plan by 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.). It details the profit distribution and capital reserve conversion to share capital approved at the 2016 annual shareholders meeting held on May 3, 2017. The document includes specifics on cash dividends per 10 shares, share bonus issuance, record dates, ex-dividend dates, and shareholding changes. The text is an announcement of the dividend and share distribution plan implementation, not the full annual report or financial statements. The document length is 2585 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2017-05-08 Chinese
关于员工持股计划终止的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the termination of an employee stock ownership plan, detailing the history, regulatory compliance, stock purchase, and final sale of shares related to the plan. It does not contain financial statements or detailed financial performance data. It is a corporate announcement about a capital/financing related event (employee stock plan termination and share sales). Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on this specific update, not a full report or regulatory filing.
2017-05-04 Chinese
2016年度股东大会的律师见证法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2016 Annual General Meeting (AGM) of 瑞康医药股份有限公司. It details the procedures of the AGM, including the convening, attendance, agenda items, voting procedures, and results. The document is not the AGM materials or presentations themselves but a legal opinion confirming the legality and validity of the AGM process and resolutions. It is not an announcement of voting results alone, nor a full annual report or financial statement. Given the nature of the document as a legal opinion on the AGM, it fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, and related official documents about the meeting. The document length (6204 characters) and detailed content support this classification with high confidence.
2017-05-03 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.